Cantor Fitzgerald Starts Bioventus Inc (BVS) at Overweight

Cantor Fitzgerald analyst Ross Osborn initiates coverage on Bioventus Inc (NASDAQ: BVS) with a Overweight rating and a price target of $12.00.

The analyst comments "Investment Summary. We initiate coverage on Bioventus, Inc. (BVS) with an Overweight rating and 12-month price target of $12. BVS is a medical technology company focused on relieving pain and addressing musculoskeletal challenges through a leading portfolio of applications in pain treatments, surgical solutions and restorative therapies. We initiate with an Overweight rating because we (1) hold a favorable view of the company's estimated $6.4 billion market; (2) believe BVS is poised for EBITDA margin expansion in the near future, supported by a high GM profile and scalable cost structure that will allow the company to reduce its outstanding debt; and (3) view the company's shares as attractively valued."

For an analyst ratings summary and ratings history on Bioventus Inc click here. For more ratings news on Bioventus Inc click here.

Shares of Bioventus Inc closed at $7.02 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Aurora Spine settles patent dispute, secures $600K insider loan